middle.news
Alterity Advances ATH434 to Phase 3 with Promising MSA Trial Data
10:02am on Tuesday 19th of May, 2026 AEST
•
Healthcare
Read Story
Alterity Advances ATH434 to Phase 3 with Promising MSA Trial Data
10:02am on Tuesday 19th of May, 2026 AEST
Key Points
Phase 2 trial shows significant slowing of MSA progression
Novel MRI imaging detects early-stage MSA and tracks iron accumulation
CSF NfL biomarker strengthens treatment effect detection and patient stratification
ATH434 granted FDA Fast Track and Orphan Drug designations
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE